Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib by Vincent D. de Jager, Jos A. Stigt, Maarten Niemantsverdriet, Arja ter Elst, Anthonie J. van der Wekken

Get full text

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification by Arenda D. Meedendorp, Arja ter Elst, Nils A. ’t Hart, Harry J. M. Groen, Ed Schuuring, Anthonie J. van der Wekken

Get full text

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nat... by Rolof G.P. Gijtenbeek, Ronald A.M. Damhuis, Anthonie J. van der Wekken, Lizza E.L. Hendriks, Harry J.M. Groen, Wouter H. van Geffen

Get full text

Molecular imaging to support cancer immunotherapy by Elisabeth GE de Vries, Marjolijn N Lub-de Hooge, Sjoukje F Oosting, Pim P van de Donk, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Derk-Jan A de Groot

Get full text

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief... by Vincent D. de Jager, MD, Léon C. van Kempen, PhD, Betzabel N. Cajiao Garcia, MSc, T. Jeroen N. Hiltermann, MD, PhD, Anthonie J. van der Wekken, MD, PhD, Ed Schuuring, PhD, Stefan M. Willems, MD, PhD

Get full text

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerResearch in context by G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen

Get full text

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer by Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken

Get full text

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, mul... by Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken

Get full text